Cytosorbents (CTSO) Total Debt Growth (1y) (2017 - 2026)
Cytosorbents (CTSO) Total Debt Growth (1y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.44 Bn | 193.84 Bn | 7.27 Bn | 142.67% |
| 2 | Stryker | 127.32 Bn | 123.85 Bn | 4.50 Bn | -9.88% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -1.95% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 1,188.16% |
| 5 | Edwards Lifesciences | 51.90 Bn | 47.65 Bn | 1.35 Bn | 0.12% |
| 6 | Dexcom | 34.30 Bn | 32.36 Bn | 830.00 Mn | - |
| 7 | GE HealthCare Technologies | 33.74 Bn | 31.63 Bn | 2.18 Bn | -17.79% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | -9.03% |
| 9 | Steris | 23.05 Bn | 22.56 Bn | 684.20 Mn | -0.50% |
| 10 | Cytosorbents | 21.98 Mn | 17.56 Mn | 7.05 Mn | 19.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.92% |
| Mar 31, 2026 | 19.54% |
| Dec 31, 2025 | 19.08% |
| Sep 30, 2025 | 5.51% |
| Jun 30, 2025 | 5.15% |
| Mar 31, 2025 | 220.35% |
| Dec 31, 2024 | 177.54% |
| Sep 30, 2024 | 174.36% |
| Jun 30, 2024 | 172.30% |
| Mar 31, 2024 | -11.62% |
| Dec 31, 2023 | 0.86% |
| Sep 30, 2020 | 372.13% |
| Jun 30, 2020 | 118.15% |
| Mar 31, 2020 | 51.41% |
| Dec 31, 2019 | 51.41% |
| Sep 30, 2019 | -67.62% |
| Jun 30, 2019 | 0.96% |
| Mar 31, 2019 | 0.96% |
| Dec 31, 2018 | -28.95% |
| Sep 30, 2018 | -23.51% |